Upcoming event
40th Annual EAU Congress
Back

Tag: ASCO GU21

Molecular and clinical characterization of mCRPC patients achieving deep PSA responses to BAT

Efficacy of PD-L1 inhibitor avelumab in NEPC/AVPC

TITAN trial

Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA)

68Ga-PSMA expression changes on PET/CT for response assessment during taxane-based chemotherapy in metastatic prostate cancer patients

Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up

MRI-guided fusion biopsy of the prostate resection bed among post-radical prostatectomy patients with rising PSA